This company has been marked as potentially delisted and may not be actively trading. ZIOPHARM Oncology (ZIOP) Short Interest Ratio & Short Volume Add Compare Share Share Short Interest Stock AnalysisBuy This Stock ZIOPHARM Oncology Short Interest DataZIOPHARM Oncology (ZIOP) has a short interest of 35.28 million shares, representing 18.12% of the float (the number of shares available for trading by the public). This marks a 3.67% increase in short interest from the previous month. The short interest ratio (days to cover) is 15.7, indicating that it would take 15.7 days of the average trading volume of 2.01 million shares to cover all short positions.Current Short Interest35,280,000 sharesPrevious Short Interest34,030,000 sharesChange Vs. Previous Month+3.67%Dollar Volume Sold Short$33.37 millionShort Interest Ratio15.7 Days to CoverLast Record DateJanuary 15, 2022Outstanding Shares216,146,000 sharesFloat Size194,670,000 sharesShort Percent of Float18.12%Today's Trading Volume2,127,500 sharesAverage Trading Volume2,008,312 sharesToday's Volume Vs. Average106% Short Selling ZIOPHARM Oncology? Sign up to receive the latest short interest report for ZIOPHARM Oncology and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartZIOP Short Interest Over TimeZIOP Days to Cover Over TimeZIOP Percentage of Float Shorted Over Time ZIOPHARM Oncology Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 1/15/202235,280,000 shares $33.37 million +3.7%18.1%15.7 $0.95 12/31/202134,030,000 shares $37.09 million -1.4%17.5%15.7 $1.09 12/15/202134,520,000 shares $43.50 million +3.9%17.7%15.8 $1.26 11/30/202133,230,000 shares $46.19 million +1.5%17.1%14.5 $1.39 11/15/202132,730,000 shares $45.49 million -0.1%16.8%9.9 $1.39 10/29/202132,750,000 shares $49.13 million +2.0%16.9%9.6 $1.50 10/15/202132,120,000 shares $54.28 million -1.1%16.6%9.5 $1.69 9/30/202132,470,000 shares $59.10 million -4.5%16.7%9.9 $1.82 9/15/202134,000,000 shares $57.46 million -0.8%17.5%10.6 $1.69 8/31/202134,280,000 shares $55.88 million -3.0%17.6%11.1 $1.63 Get the Latest News and Ratings for ZIOP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for ZIOPHARM Oncology and its competitors with MarketBeat's FREE daily newsletter. 8/13/202135,350,000 shares $62.92 million -3.1%18.1%18.8 $1.78 7/30/202136,470,000 shares $82.79 million +2.2%18.7%21.5 $2.27 7/15/202135,670,000 shares $83.11 million +1.3%18.3%21.4 $2.33 6/30/202135,220,000 shares $92.98 million -5.6%18.0%21 $2.64 6/15/202137,300,000 shares $104.81 million -0.1%19.1%22.1 $2.81 5/28/202137,340,000 shares $113.51 million -3.6%19.1%21.2 $3.04 5/14/202138,750,000 shares $117.41 million -1.6%N/A20.5 $3.03 4/30/202139,380,000 shares $135.86 million +0.9%N/A18 $3.45 4/15/202139,020,000 shares $134.62 million -0.9%N/A14.8 $3.45 3/31/202139,390,000 shares $132.74 million +11.3%N/A14 $3.37 3/15/202135,380,000 shares $155.32 million +0.5%N/A11.4 $4.39 2/26/202135,200,000 shares $163.68 million +3.7%N/A11.9 $4.65 2/12/202133,940,000 shares $165.97 million +5.8%N/A12.4 $4.89 1/29/202132,070,000 shares $120.90 million -1.6%N/A12.6 $3.77 1/15/202132,580,000 shares $114.36 million -2.8%N/A14.9 $3.51 12/31/202033,510,000 shares $88.80 million +0.3%N/A17.7 $2.65 12/15/202033,410,000 shares $103.24 million +0.2%N/A20.2 $3.09 11/30/202033,350,000 shares $97.05 million -0.3%N/A21.9 $2.91 10/30/202033,490,000 shares $73.34 million -3.2%N/A21.1 $2.19 10/15/202034,610,000 shares $93.10 million +2.5%N/A21.9 $2.69 9/30/202033,770,000 shares $85.10 million +7.6%N/A21.4 $2.52 9/15/202031,400,000 shares $92.63 million +0.2%N/A17.5 $2.95 8/31/202031,350,000 shares $88.09 million -1.8%N/A16.8 $2.81 8/14/202031,920,000 shares $94.16 million -0.7%N/A15.8 $2.95 7/31/202032,130,000 shares $95.43 million -1.0%N/A16.4 $2.97 7/15/202032,440,000 shares $107.38 million +1.0%N/A16.5 $3.31 6/30/202032,130,000 shares $105.39 million +28.4%N/A16.5 $3.28 ZIOP Short Interest - Frequently Asked Questions What is ZIOPHARM Oncology's current short interest? Short interest is the volume of ZIOPHARM Oncology shares that have been sold short but have not yet been closed out or covered. As of January 15th, traders have sold 35,280,000 shares of ZIOP short. 18.12% of ZIOPHARM Oncology's shares are currently sold short. Learn More on ZIOPHARM Oncology's current short interest. What is a good short interest ratio for ZIOPHARM Oncology? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ZIOP shares currently have a short interest ratio of 16.0. Learn More on ZIOPHARM Oncology's short interest ratio. What is a good short interest percentage for ZIOPHARM Oncology? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 18.12% of ZIOPHARM Oncology's floating shares are currently sold short. Is ZIOPHARM Oncology's short interest increasing or decreasing? ZIOPHARM Oncology saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 35,280,000 shares, an increase of 3.7% from the previous total of 34,030,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is ZIOPHARM Oncology's float size? ZIOPHARM Oncology currently has issued a total of 216,146,000 shares. Some of ZIOPHARM Oncology's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. ZIOPHARM Oncology currently has a public float of 194,670,000 shares. How does ZIOPHARM Oncology's short interest compare to its competitors? 18.12% of ZIOPHARM Oncology's shares are currently sold short. Here is how the short interest of companies in the industry of "biotechnology" compare to ZIOPHARM Oncology: Regulus Therapeutics Inc. (3.65%), Myriad Genetics, Inc. (9.85%), Rigel Pharmaceuticals, Inc. (11.46%), Emergent BioSolutions Inc. (15.08%), Verastem, Inc. (27.19%), XOMA Co. (1.74%), Vanda Pharmaceuticals Inc. (8.66%), Bolt Biotherapeutics, Inc. (1.71%), Lexicon Pharmaceuticals, Inc. (16.92%), Codexis, Inc. (6.79%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Advanced Micro Devices, Inc. ($8.74 billion), S&P Global Inc. ($7.90 billion), Charter Communications, Inc. ($5.88 billion), Lucid Group, Inc. ($3.75 billion), Palo Alto Networks, Inc. ($3.44 billion), Wayfair Inc. ($2.88 billion), Rivian Automotive, Inc. ($2.60 billion), Zscaler, Inc. ($1.86 billion), Match Group, Inc. ($1.79 billion), and Carnival Co. & plc ($1.72 billion). View all of the most shorted stocks. What does it mean to sell short ZIOPHARM Oncology stock? Short selling ZIOP is an investing strategy that aims to generate trading profit from ZIOPHARM Oncology as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against ZIOPHARM Oncology? A short squeeze for ZIOPHARM Oncology occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ZIOP, which in turn drives the price of the stock up even further. How often is ZIOPHARM Oncology's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ZIOP, twice per month. The most recent reporting period available is January, 15 2022. More Short Interest Resources from MarketBeat Related Companies Regulus Therapeutics Short Squeeze Myriad Genetics Short Squeeze Rigel Pharmaceuticals Short Squeeze Emergent BioSolutions Short Squeeze Verastem Short Squeeze XOMA Short Squeeze Vanda Pharmaceuticals Short Squeeze Bolt Biotherapeutics Short Squeeze Lexicon Pharmaceuticals Short Squeeze Codexis Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ZIOP) was last updated on 6/16/2025 by MarketBeat.com Staff From Our PartnersAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBREAKING: Trump vs. Elon Feud Threatens Your Retirement – Protect Yourself NOW"This isn't just a war of words. This is a financial time bomb. The escalating battle between Donald Trump a...American Alternative | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. Chinese AI chatbot DeepSeek turned the tech world on its hea...Weiss Ratings | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZIOPHARM Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ZIOPHARM Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.